Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership lessened its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 16.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,127,162 shares of the biopharmaceutical company’s stock after selling 228,447 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Alnylam Pharmaceuticals were worth $448,216,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of ALNY. Brighton Jones LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $243,000. Geneos Wealth Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 372.3% in the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 175 shares in the last quarter. Flow Traders U.S. LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at about $241,000. Daiwa Securities Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after purchasing an additional 35 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 70,300.0% in the second quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock valued at $229,000 after purchasing an additional 703 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $282.85 on Friday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13. The company has a market capitalization of $37.76 billion, a price-to-earnings ratio of 77.28 and a beta of 0.29. The company’s 50 day simple moving average is $304.31 and its 200 day simple moving average is $343.68. Alnylam Pharmaceuticals, Inc. has a 1 year low of $281.77 and a 1 year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $1.12. The business had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The company’s quarterly revenue was up 96.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.44) earnings per share. On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.47 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Truist Financial reduced their price target on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating on the stock in a report on Monday, April 13th. Citigroup assumed coverage on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $510.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, June 4th. Canaccord Genuity Group upped their price target on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Finally, Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $463.13.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the transaction, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This represents a 70.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the transaction, the insider directly owned 9,443 shares in the company, valued at $3,120,156.06. The trade was a 19.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 7,740 shares of company stock worth $2,420,214 in the last three months. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.